(Q38213840)

31 August 2017

title

Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence (English)

1 reference

31 August 2017

1 reference

E Kanal

1

1 reference

31 August 2017

K Maravilla

series ordinal

2

1 reference

31 August 2017

H A Rowley

series ordinal

3

1 reference

31 August 2017

language of work or name

1 reference

22 May 2014

1 reference

American Journal of Neuroradiology

31 August 2017

published in

1 reference

31 August 2017

volume

35

1 reference

31 August 2017

issue

12

1 reference

31 August 2017

page(s)

2215-2226

1 reference

Extracellular gadolinium-based contrast media: an overview

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA).

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Phase III, randomized, double-blind, cross-over comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Diagnostic yield of double-dose gadobutrol in the detection of brain metastasis: intraindividual comparison with double-dose gadopentetate dimeglumine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Sequential dynamic gadolinium magnetic resonance perfusion-weighted imaging: effects on transit time and cerebral blood volume measurements.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 Tesla.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Comparison of quantitative dynamic susceptibility-contrast MRI perfusion estimates obtained using different contrast-agent administration schemes at 3T.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Improved vessel delineation in keyhole time-resolved contrast-enhanced MR angiography using a gadolinium doped flush.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Multicenter, intraindividual comparison of single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine for MR angiography of the supra-aortic arteries (the Supra-Aortic VALUE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced magnetic resonance angiography of the supraaortic vessels at 3 Tesla

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Dynamic and static magnetic resonance angiography of the supra-aortic vessels at 3.0 T: intraindividual comparison of gadobutrol, gadobenate dimeglumine, and gadoterate meglumine at equimolar dose.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Role of thermodynamic and kinetic parameters in gadolinium chelate stability

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Prevalence of acute adverse reactions to gadobutrol--a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Incidence of immediate gadolinium contrast media reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Immediate hypersensitivity reaction to gadolinium-based MR contrast media

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Adverse reactions to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Anaphylactic shock after first exposure to gadoterate meglumine: two case reports documented by positive allergy assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Safety of approved MR contrast media for intravenous injection

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Urographic Contrast Media Reactions and Anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Model of the human vasculature for studying the influence of contrast injection speed on cerebral perfusion MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III)

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Signal quality of single dose gadobenate dimeglumine pulmonary MRA examinations exceeds quality of MRA performed with double dose gadopentetate dimeglumine

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the Peripheral VALUE Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

Brain mr perfusion imaging in humans : Advantages of high-molarity gadolinium chelates

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3917

21 January 2018

Identifiers

DOI

10.3174/AJNR.A3917

1 reference

31 August 2017

1 reference